Ausgabe 5/2016
Inhalt (7 Artikel)
What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
- Acute Myeloid Leukemias (H Erba, Section Editor)
Hugo F. Fernandez
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update
- Open Access
- Myeloproliferative Disorders (C Harrison, Section Editor)
Neha Bhatnagar, Laure Nizery, Oliver Tunstall, Paresh Vyas, Irene Roberts
Investigation and Management of Erythrocytosis
- Myeloproliferative Disorders (C Harrison, Section Editor)
Mary Frances McMullin
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
- Open Access
- Myeloproliferative Disorders (C Harrison, Section Editor)
Gunnar Birgegård
How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera
- Myeloproliferative Disorders (C Harrison, Section Editor)
Andreas Reiter, Claire Harrison
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
- CART and Immunotherapy (M Ruella, Section Editor)
Marco Ruella, Carl H. June
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances
- Acute Lymphocytic Leukemias (K Ballen, Section Editor)
Lynda M. Vrooman, Lewis B. Silverman